Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk

Randomized controlled trials (RCTs) show that decreases in low-density lipoprotein cholesterol (LDL-C) by the use of statins cause a significant reduction in the development of cardiovascular disease (CVD). However, one of our previous studies showed that, among eight RCTs that investigated the effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Hidekatsu, Adachi, Hiroki, Hakoshima, Mariko, Katsuyama, Hisayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657259/
https://www.ncbi.nlm.nih.gov/pubmed/36362288
http://dx.doi.org/10.3390/ijms232113499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657259/
https://www.ncbi.nlm.nih.gov/pubmed/36362288
http://dx.doi.org/10.3390/ijms232113499

Ejemplares similares